Open an account

4D Molecular Therapeutics

FDMT · NASDAQ

$13.10+$0.81 (+6.59%)TodayMarket closed ·
Prev close $12.29

About FDMT

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. The company is headquartered in Emeryville, California and currently employs 196 full-time employees. The company went IPO on 2020-12-11. The firm's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The firm is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The firm's non-core programs include 4D-175, 4D-725, and 4D-310.

Employees
196
Headquarters
Emeryville, California
Listed
Dec 11, 2020
Sector
Health Care
Industry
Biotechnology
Website
4dmoleculartherapeutics.com

FDMT key statistics

Market cap
723.70M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.03M
Volume
725.39K
Open price
$12.29
High today
$13.39
Low today
$12.29
52 Week high
$16.93
52 Week low
$6.96

4D Molecular Therapeutics (FDMT) at a glance

4D Molecular Therapeutics (FDMT) last traded at $13.10, with a market cap of 723.70M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $12.29 and $13.39. The current price is 6.6% above the day's low and 2.2% below its high.

Volume so far is 725.39K shares, below the average of 1.03M shares a day.

Over the past year 4D Molecular Therapeutics has ranged from $6.96 to $16.93, and now sits 62% of the way up that range.

4D Molecular Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$1.04 per share against an estimate of -$1.04.

The average analyst price target is $28.75, 119.4% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 10 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 13 analystsAvg $28.75
Low
$18.18
Now
$13.10
High
$38.85

FDMT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 52.6% on average.

  1. Q3 FY24: reported -$0.79 per share against an estimate of -$0.7152
  2. Q4 FY24: reported -$0.90 per share against an estimate of -$0.8343
  3. Q1 FY25: reported -$0.86 per share against an estimate of -$0.8795
  4. Q2 FY25: reported -$0.98 per share against an estimate of -$0.8933
  5. Q3 FY25: reported -$1.01 per share against an estimate of -$0.9982
  6. Q4 FY25: reported $0.43 per share against an estimate of -$0.7777
  7. Q1 FY26: reported -$1.01 per share against an estimate of -$1.01
  8. Q2 FY26: reported -$1.04 per share against an estimate of -$1.04

FDMT news

  • Vandana Singh

    4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win

  • Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings)

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Beyond The Numbers: 4 Analysts Discuss 4D Molecular Therapeutics Stock

  • 10 Health Care Stocks Whale Activity In Today's Session

  • Avi Kapoor

    Jim Cramer: AppLovin Calls For Prudence, This Health Care Stock Is 'Pure Spec'

  • What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics

  • 12 Health Care Stocks Moving In Monday's Intraday Session

Similar companies

Companies in the same industry as 4D Molecular Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.